ValuEngine Lowers TESARO (TSRO) to Hold

ValuEngine lowered shares of TESARO (NASDAQ:TSRO) from a buy rating to a hold rating in a research report released on Wednesday morning.

Other research analysts have also issued reports about the company. HC Wainwright dropped their target price on TESARO to $71.00 and set a buy rating on the stock in a research report on Friday, July 20th. Citigroup dropped their target price on TESARO from $100.00 to $85.00 and set a buy rating on the stock in a research report on Wednesday, August 29th. Cann reaffirmed a buy rating and issued a $83.00 target price on shares of TESARO in a research report on Tuesday, September 4th. Guggenheim started coverage on TESARO in a research report on Monday, September 17th. They issued a buy rating on the stock. Finally, BidaskClub raised TESARO from a hold rating to a buy rating in a research report on Friday, October 5th. Nine analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $78.26.

TESARO stock traded down $1.17 during mid-day trading on Wednesday, hitting $31.50. The company’s stock had a trading volume of 1,622,456 shares, compared to its average volume of 1,724,089. The company has a debt-to-equity ratio of 3.74, a current ratio of 4.11 and a quick ratio of 3.64. TESARO has a 52-week low of $25.62 and a 52-week high of $119.00.



TESARO (NASDAQ:TSRO) last issued its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($3.04) earnings per share for the quarter, missing the consensus estimate of ($2.66) by ($0.38). TESARO had a negative return on equity of 285.30% and a negative net margin of 180.29%. The firm had revenue of $57.21 million during the quarter, compared to analyst estimates of $65.50 million. During the same period in the previous year, the company earned ($2.82) earnings per share. The business’s revenue for the quarter was up 94.2% on a year-over-year basis. On average, equities analysts forecast that TESARO will post -11.15 earnings per share for the current fiscal year.

In other TESARO news, Director Arnold L. Oronsky sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 7th. The stock was sold at an average price of $26.77, for a total value of $267,700.00. Following the completion of the sale, the director now owns 12,479 shares in the company, valued at approximately $334,062.83. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 10,630 shares of company stock valued at $290,424 in the last quarter. Corporate insiders own 33.70% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. KBC Group NV lifted its position in shares of TESARO by 20.0% during the 2nd quarter. KBC Group NV now owns 10,533 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 1,752 shares during the period. Rhumbline Advisers lifted its position in shares of TESARO by 5.0% during the 2nd quarter. Rhumbline Advisers now owns 39,787 shares of the biopharmaceutical company’s stock worth $1,769,000 after buying an additional 1,885 shares during the period. Trellus Management Company LLC lifted its position in shares of TESARO by 20.0% during the 2nd quarter. Trellus Management Company LLC now owns 13,819 shares of the biopharmaceutical company’s stock worth $615,000 after buying an additional 2,300 shares during the period. Russell Investments Group Ltd. lifted its position in shares of TESARO by 54.1% during the 1st quarter. Russell Investments Group Ltd. now owns 8,498 shares of the biopharmaceutical company’s stock worth $485,000 after buying an additional 2,985 shares during the period. Finally, Xact Kapitalforvaltning AB lifted its position in shares of TESARO by 86.8% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 6,700 shares of the biopharmaceutical company’s stock worth $298,000 after buying an additional 3,113 shares during the period.

TESARO Company Profile

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Featured Article: Price to Earnings Ratio (PE)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply